Regeneron Pharmaceuticals, Inc. (REGN)

Precedente Chiudi:

$890.66

Aprire:

$889.41

Volume 24 ore:

87,701

Capitalizzazione di mercato:

$98.14B

Reddito:

$13.12B

Utile/perdita netta:

$3.95B

Rapporto P/E:

25.64

EPS:

35.06

Flusso di cassa netto:

$3.67B

1 W Prestazione:

-1.05%

1M Prestazione:

-7.46%

6M Prestazione:

+13.36%

1 anno Prestazione:

+11.19%

Intervallo 1D:

$888.52

$898.73

Portata 52W:

$684.80

$998.33

Regeneron Pharmaceuticals, Inc. Stock (REGN) Company Profile

Nome

Regeneron Pharmaceuticals, Inc.

Settore

Healthcare (1201)

Industria

Biotechnology (682)

Telefono

914-847-7000

Indirizzo

777 Old Saw Mill River Road, Tarrytown, NY

Dipendente

6,763

Cinguettio

@regeneron

Prossima data di guadagno

2024-05-02

Ultimi documenti SEC

REGN's Discussions on Twitter

Regeneron Pharmaceuticals, Inc. Stock (REGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Overweight
2021-12-07	Ripresa	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Ripresa	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Ripresa	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Mostra tutto

Regeneron Pharmaceuticals, Inc. Borsa (REGN) Ultime notizie

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Zacks Investment Research

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

Zacks Investment Research

Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround

Zacks Investment Research

Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks Investment Research

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

GlobeNewswire Inc.

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks Investment Research

Regeneron Pharmaceuticals, Inc. Azioni (REGN) Dati Finanziari

Regeneron Pharmaceuticals, Inc. (REGN) Reddito 2024

Regeneron Pharmaceuticals, Inc. (REGN) Reddito netto 2024

Regeneron Pharmaceuticals, Inc. (REGN) Flusso di cassa 2024

Regeneron Pharmaceuticals, Inc. (REGN) Utile per azione 2024

Regeneron Pharmaceuticals, Inc. Azioni (REGN) insider trading